Table 3.
Hazard ratio* of acute care encounters and other outcomes for new users of overactive bladder medications after 4:1 (anticholinergic:mirabegron) matching on hdPS scores†
| Outcome | Primary analysis | Sensitivity analyses | |
|---|---|---|---|
| 90-day HR (95% CI)‡ |
30-day HR (95% CI)‡ |
180-day HR (95% CI)‡ |
|
| Any acute care encounter¶ | 1.23 (1.12-1.37) | 1.34 (1.15-1.56) | 1.22 (1.12-1.33) |
| Acute care encounters¶ for any anticholinergic related AEs§ | 1.18 (1.04-1.34) | 1.33 (1.10-1.61) | 1.16 (1.04-1.30) |
| Fracture of hip/thigh/pelvis | 1.30 (0.72-2.32) | 2.23 (0.77-6.46) | 1.05 (0.66-1.66) |
| Unintentional traumatic injury | 1.05 (0.89-1.23) | 1.07 (0.84-1.36) | 1.12 (0.97-1.28) |
| Constipation/Urinary retention | 1.51 (1.24-1.84) | 2.05 (1.50-2.80) | 1.38 (1.17-1.63) |
| Fall | 1.04 (0.74-1.46) | 1.34 (0.77-2.34) | 1.08 (0.82-1.43) |
| Dizziness/Vertigo | 1.00 (0.73-1.35) | 1.21 (0.76-1.92) | 1.05 (0.80-1.37) |
CI=confidence interval, hdPS=high-dimensional propensity score, HR=hazard ratio
*
Reference group = mirabegron
†
hdPS includes demographics, predefined variables, and empirically selected variables
‡
Statistically significant values are highlighted in bold type
§
Composite of fracture of hip/thigh/pelvis, unintentional traumatic injury, constipation/urinary retention, fall, and dizziness/vertigo
¶
All-cause emergency department visit or non-elective hospitalization